Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

4 articles from the last 30 days matching "Noma"

Clinical trialUNITERAREYesterday

New Recruiting Trial: Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy

Researchers are testing a new treatment for head and neck cancer that comes back after radiation therapy. The treatment combines radiation therapy again with a drug called chidamide, which helps boost the body's immune system to fight cancer cells. This is an early-stage study (Phase 1) just starting to recruit patients in 2026.

WHY IT MATTERSThis trial offers a potential new option for patients with recurrent head and neck squamous cell carcinoma who have limited treatment choices after their cancer returns following initial radiation therapy.
👁 Watch this spacehead and neck squamous cell carcinomaRead →
ResearchPUBMEDApr 29

Adenocarcinoma of the small intestine cohort: prospectively collecting real-world data to improve care and quality of life for patients with a rare cancer.

Researchers in the Netherlands are creating a large database to collect information about small intestinal adenocarcinoma, a rare type of cancer that starts in the small intestine. They're gathering medical records, tumor samples, and patient feedback to better understand how this cancer develops and which treatments work best. This study is important because doctors currently don't have enough information to know the best way to treat this disease.

WHY IT MATTERSFor the first time, patients with small intestinal adenocarcinoma will have their disease studied systematically in a large prospective cohort, which could lead to treatment recommendations tailored specifically to this rare cancer instead of borrowed from other gastrointestinal cancers.
ℹ Good to knowsmall intestinal adenocarcinomaadenocarcinoma of the small intestineRead →
Clinical trialCLINICALTRIALSApr 17

Trial Now Recruiting: Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma (NCT06947928)

Researchers are testing a new treatment called IFx-Hu2.0 combined with a cancer drug called pembrolizumab for people with Merkel cell carcinoma, a rare and aggressive skin cancer. In this study, some patients will receive the new treatment while others receive a placebo (fake treatment) to see which works better. The trial is looking for 118 adults to participate and is currently accepting new patients.

WHY IT MATTERSThis is the first Phase 2/3 trial testing IFx-Hu2.0 as an add-on therapy for Merkel cell carcinoma, offering checkpoint inhibitor-naïve patients a potential new treatment option beyond standard pembrolizumab alone.
→ You can act on thisMerkel cell carcinomaRead →
Clinical trialUNITERAREApr 15

New Recruiting Trial: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Researchers are testing a new cancer treatment that combines two approaches: a chemotherapy drug called temozolomide and a vaccine called SurVaxM that trains the immune system to fight cancer cells. This trial is for patients with neuroendocrine carcinomas (rare cancers in hormone-producing cells) that are spreading and getting worse despite other treatments. The study is now accepting patients and will run through 2026.

WHY IT MATTERSThis is one of the first trials testing an immunotherapy vaccine specifically for metastatic neuroendocrine carcinomas, offering a potential new option for patients whose cancer has progressed on standard treatments.
→ You can act on thisneuroendocrine carcinomametastatic neuroendocrine carcinomaRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases